Supplementary data crisaborole/dupi

Description

Supplementary material. Full methodology Supplementary Table I. Reasons for exclusion of studies. Supplementary Table II. Conclusions of crisaborole commentorials Supplementary Table III. Non-English language studies included Supplementary Table IV. Dupilumab extracted data Supplementary Table V. Crisaborole extracted data

Categories

Licence